— Know what they know.
Not Investment Advice

PODD NASDAQ

Insulet Corp.
1W: +5.1% 1M: +9.7% 3M: -10.9% YTD: -47.2% 1Y: -53.9% 3Y: +2.8% 5Y: -48.9%
$150.22
+0.96 (+0.65%)
 
Weekly Expected Move ±4.4%
$136 $143 $149 $156 $162
NASDAQ · Healthcare · Medical - Devices · Tech Score Buy · Power 77 · $10.4B mcap · 69M float · 2.38% daily turnover · Short 46% of daily vol
Credit Risk of going bust: lower than 65% of companies Debt: 8.4% of company value Bonds: $39.1M held by 117 funds, 168 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.35 (down 99.1%), Insulet Corp. would be worth roughly what it owes.
Total debt $948.4M against a stock market value of $10.35B.
Distance to default 6.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $483.6M (short-term plus half of long-term), stock volatility 46.5%; Altman Z 5.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Bullish 100
Insider+$0.6M
Congress3 trades
ETF Holdings—
Key Statistics
Market Cap$10.4B
52W Range126.4-354.88
Volume1,525,628
Avg Volume1,640,942
Beta1.10
Dividend—
Analyst Ratings
28 Buy 19 Hold 3 Sell
Consensus Buy
Company Info
CEOAshley McEvoy
Employees5,400
SectorHealthcare
IndustryMedical - Devices
IPO Date2007-05-15
100 Nagog Park
Acton, MA 01720
US
978 600 7000
About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Pease Flavia F-InKind 1,882 $130.79 2026-10-01
MAZELSKY JONATHAN JA A-Award 141 $130.47 2026-09-30
Huffines Robert Luth A-Award 178 $130.47 2026-09-30
McEvoy Ashley P-Purchase 1,100 $147.47 2026-08-21
Davis Lisa Blair F-InKind 244 $165.35 2026-08-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms